PKO Investment Management Joint Stock Co Sells 1,200 Shares of Stryker Corporation $SYK

PKO Investment Management Joint Stock Co reduced its holdings in shares of Stryker Corporation (NYSE:SYK) by 23.1% in the second quarter, according to its most recent filing with the SEC. The fund owned 4,000 shares of the medical technology company’s stock after selling 1,200 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Stryker were worth $1,583,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of SYK. Brighton Jones LLC increased its holdings in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Stryker by 16.4% in the 1st quarter. GAMMA Investing LLC now owns 5,574 shares of the medical technology company’s stock valued at $2,075,000 after buying an additional 785 shares during the period. Spire Wealth Management lifted its holdings in shares of Stryker by 1.2% in the 1st quarter. Spire Wealth Management now owns 3,473 shares of the medical technology company’s stock valued at $1,293,000 after buying an additional 42 shares during the period. Golden State Wealth Management LLC lifted its holdings in shares of Stryker by 298.5% in the 1st quarter. Golden State Wealth Management LLC now owns 793 shares of the medical technology company’s stock valued at $295,000 after buying an additional 594 shares during the period. Finally, HBK Sorce Advisory LLC lifted its holdings in shares of Stryker by 5.0% in the 1st quarter. HBK Sorce Advisory LLC now owns 847 shares of the medical technology company’s stock valued at $315,000 after buying an additional 40 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on SYK shares. UBS Group set a $408.00 price objective on Stryker in a report on Monday, October 13th. Rothschild Redb upgraded Stryker to a “hold” rating in a research note on Thursday, September 18th. Barclays lifted their price target on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday. BTIG Research lifted their price target on Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Finally, Truist Financial cut their price target on Stryker from $415.00 to $407.00 and set a “hold” rating for the company in a research note on Wednesday, October 15th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $432.24.

Stryker Price Performance

NYSE:SYK opened at $381.86 on Friday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock has a 50 day moving average of $379.84 and a two-hundred day moving average of $379.73. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm has a market cap of $145.99 billion, a P/E ratio of 50.58, a price-to-earnings-growth ratio of 2.76 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period in the prior year, the business earned $2.81 earnings per share. The business’s revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio is presently 44.50%.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.